The modest EPS beat is unlikely to drive sustained price movement given the pre-revenue status. Monitor upcoming pipeline catalysts and cash runway updates in the Q2 2026 full earnings release on August 12, 2026.
Price Chart
Executive Summary
Kura Oncology reported Q1 2026 EPS of -$0.83, beating the consensus estimate of -$0.88 by 5.2%. The beat is modest and the company remains pre-revenue with no revenue reported, making the EPS surprise a mechanical artifact rather than a sign of fundamental improvement. The stock's historical performance shows mixed T+20 outcomes with a 56% win rate, suggesting limited directional conviction from this filing alone.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.83 beat consensus of -$0.88 by 5.2%
- No revenue reported; company is pre-revenue clinical-stage biotech
- Consensus for next quarter (Jun 2026) is -$0.89 EPS
- Historical T+20 win rate on KURA reports is 56% with average alpha of +3.83%
Financial Impact
EPS beat of $0.05 vs consensus; no revenue to evaluate
Risk Factors
- No revenue stream; entirely dependent on clinical trial outcomes and financing
- High cash burn rate typical of clinical-stage biotech
- Next-quarter consensus EPS of -$0.89 suggests continued losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3339211 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $12.09 $11.37 | ▼ −6.00% | ▼ −5.66% | $10.65 (−11.91%) |
Sep 8, 2026 24d ago | 8-K | $12.52 $11.30 | ▼ −9.74% | ▼ −8.63% | $10.65 (−14.94%) |
Aug 24, 2026 5w ago | Insider Cluster | $12.40 $12.65 | ▲ +2.02% | ▲ +1.55% | $10.65 (−14.11%) |
Aug 21, 2026 6w ago | Insider Cluster | $11.89 $12.66 | ▲ +6.48% | ▲ +6.00% | $10.65 (−10.43%) |
Aug 17, 2026 6w ago | Insider Buy | $12.33 $13.59 | ▲ +10.22% | ▲ +10.42% | $10.65 (−13.63%) |
Aug 12, 2026 7w ago | Press Release | $10.09 $11.71 | ▲ +16.06% | ▲ +18.02% | $10.65 (+5.55%) |
Aug 5, 2026 8w ago | Press Release | $9.20 $9.94 | ▲ +8.04% | ▲ +7.69% | $10.65 (+15.76%) |
Jul 29, 2026 9w ago | 8-K | $9.31 $9.28 | ▼ −0.32% | ▼ −3.94% | $10.65 (+14.39%) |
Jul 14, 2026 11w ago | Press Release | $11.24 $10.68 | ▼ −4.98% | ▼ −3.69% | $10.65 (−5.25%) |
Jun 3, 2026 17w ago | Press Release | $8.66 $8.68 | ▲ +0.29% | ▲ +4.11% | $10.65 (+23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access